Sai Life Sciences

Sai Life Sciences delivered a strong FY26 with 29% revenue growthCurrent reported value: 29% revenue growth. No comparable prior figure is available in the source record., 56% EBITDA growthCurrent reported value: 56% EBITDA growth. No comparable prior figure is available in the source record., and 109% PAT growthCurrent reported value: 109% PAT growth. No comparable prior figure is available in the source record., driven by deepening large pharma relationships (19 of top 25, contributing 49%Current 49%. Reported change: +21pp vs FY22. of revenue vs 28% in FY22) and balanced CRO/CDMO performance. The CDMO segment grew 33%, CRO 24%. Management reiterated a 15-20% revenue growthCurrent reported value: 15-20% revenue growth. No comparable prior figure is available in the source record. and 28-30% EBITDA marginCurrent reported value: 28-30% EBITDA margin. No comparable prior figure is available in the source record. guidance over three years, but flagged near-term headwinds from geopolitical tensions impacting input costs and logistics. A sharp capex increase to ₹1,100-1,300 crCurrent ₹1,100-1,300 Cr. Reported change: +74% vs FY26 actual of ₹633 Cr.ore in FY27 (vs ₹633 crore in FY26) reflects strong demand visibility from strategic customer partnerships, with 75% allocated to capacity expansion. However, execution risk remains as new capacities come online, with H2 expected stronger than H1. The key risk is that cost recovery from customers may lag cost increases, pressuring margins.